Divi's Laboratories Ltd.
DIVISLAB
5540.25
0.00 (1.09%)The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
Shareholding Pattern
| On | Ind. Pro. | Fore. Pro. | FII/FPI | Mutual Funds | Banks | Insurance | Others | Non/Institution |
|---|---|---|---|---|---|---|---|---|
| 2024-09 | 51.89 | 0 | 17.25 | 11.92 | 0 | 8.56 | 0.58 | 9.8 |
| 2024-06 | 51.9 | 0 | 16.16 | 13.1 | 0 | 8.03 | 0.64 | 10.18 |
| 2024-03 | 51.92 | 0 | 14.68 | 14.28 | 0 | 7.24 | 0.69 | 11.19 |
| 2023-12 | 51.92 | 0 | 14.85 | 13.72 | 0.22 | 7.21 | 0.74 | 11.34 |
| 2023-09 | 51.93 | 0 | 14.6 | 13.62 | 0.18 | 7.17 | 0.77 | 11.73 |
| 2023-06 | 51.93 | 0 | 14.69 | 13.2 | 0.12 | 6.91 | 1.01 | 12.14 |
| 2023-03 | 51.94 | 0 | 14.67 | 13.15 | 0.11 | 6.78 | 1.03 | 12.31 |
| 2022-12 | 51.94 | 0 | 15.15 | 12.68 | 0.12 | 6.76 | 1.11 | 12.24 |
| 2022-09 | 51.94 | 0 | 15.4 | 13.62 | 0.11 | 5.81 | 1.24 | 11.87 |
Results
| On | Income from Inv. | Int. on Bank Bal. | Int. on Advances | Other Int. | Interest Earned | Interest Exp. | Net Interest Income | Expenditure | Operating Income | Other Income | Prov. & Contingencies | PBT | Tax | PAT | Net Profit | Consolidated Net Profit | Adjusted EPS(Rs.) | Gross NPA | Gross NPA(%) | Net NPA | Net NPA(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09 | 0 | 0 | 0 | 0 | 2338 | 1 | 2337 | 1622 | 822 | 106 | 0 | 722 | 212 | 510 | 510 | 510 | 19.25 | 0 | 0% | 0 | 0% |
| 2024-06 | 0 | 0 | 0 | 0 | 2118 | 0 | 2118 | 1496 | 701 | 79 | 0 | 604 | 174 | 430 | 430 | 430 | 16.23 | 0 | 0% | 0 | 0% |
| 2024-03 | 0 | 0 | 0 | 0 | 2303 | 2 | 2301 | 1572 | 810 | 79 | 0 | 713 | 175 | 538 | 538 | 538 | 20.30 | 0 | 0% | 0 | 0% |
| 2023-12 | 0 | 0 | 0 | 0 | 1855 | 0 | 1855 | 1366 | 584 | 95 | 0 | 489 | 131 | 358 | 358 | 358 | 13.51 | 0 | 0% | 0 | 0% |
| 2023-09 | 0 | 0 | 0 | 0 | 1909 | 1 | 1908 | 1430 | 565 | 86 | 0 | 469 | 121 | 348 | 348 | 348 | 13.13 | 0 | 0% | 0 | 0% |
| 2023-06 | 0 | 0 | 0 | 0 | 1778 | 0 | 1778 | 1274 | 585 | 81 | 0 | 492 | 136 | 356 | 356 | 356 | 13.43 | 0 | 0% | 0 | 0% |
| 2023-03 | 0 | 0 | 0 | 0 | 1951 | 0 | 1951 | 1464 | 553 | 66 | 0 | 466 | 145 | 321 | 321 | 321 | 12.11 | 0 | 0% | 0 | 0% |
| 2022-12 | 0 | 0 | 0 | 0 | 1708 | 0 | 1708 | 1299 | 522 | 113 | 0 | 435 | 129 | 306 | 306 | 306 | 11.55 | 0 | 0% | 0 | 0% |
| 2022-09 | 0 | 0 | 0 | 0 | 1855 | 0 | 1855 | 1234 | 701 | 80 | 0 | 615 | 122 | 493 | 493 | 493 | 18.60 | 0 | 0% | 0 | 0% |
| 2022-06 | 0 | 0 | 0 | 0 | 2255 | 0 | 2255 | 1407 | 936 | 88 | 0 | 852 | 150 | 702 | 702 | 702 | 26.45 | 0 | 0% | 0 | 0% |